Background and Objectives: The optimal management of dilated ascending aorta during aortic valve replacement (AVR) in older or high-risk patients remains debated. While graft replacement is the standard procedure, reductive ascending aortoplasty (RAA) may offer a less invasive, tissue-preserving alternative. This study evaluated long-term RAA outcomes and identified the optimal patient profile. Materials and Methods: In a single-center cohort, 64 patients underwent AVR with unwrapped RAA (2005–2025). Patients were stratified by valve phenotype (tricuspid [TAV], n = 45; bicuspid [BAV], n = 19) and age (<70 years, n = 52; ≥70 years, n = 12). Endpoints were early safety, long-term survival, and aortic redilatation (≥50 mm). Results: Outcomes diverged markedly by subgroup. Patients aged ≥70 years demonstrated excellent 10-year freedom from redilatation (83.3%) with no reinterventions. In contrast, BAV patients had higher redilatation rates (31.6% vs. 8.9%; p = 0.053) and a trend toward more reexploration for bleeding (15.8% vs. 6.7%; p = 0.109). Redilatation and reintervention were concentrated in patients <70 years. Conclusions: RAA with AVR offers favorable long-term durability, but success is highly age-dependent. The procedure is a safe, effective tissue-preserving strategy for selected older patients (≥70 years), particularly those with TAV. However, high redilatation rates in BAV patients suggest that RAA should be avoided in this population, reinforcing graft replacement as preferred for younger patients.
Objective: This study aimed to evaluate the long‐term efficacy of a standardized triple procedure—coronary artery bypass grafting (CABG), chordal‐sparing mitral valve replacement, and tricuspid annuloplasty—in high‐risk patients with end‐stage ischemic dilated cardiomyopathy (IsDCM) for whom heart transplantation was not an option. Primary endpoints were survival, reverse ventricular remodeling, and functional recovery. Methods: We prospectively analyzed 42 consecutive patients (mean age 64.7 ± 9.1 years; 85.7% male) with end‐stage IsDCM. All presented with severe secondary mitral and tricuspid regurgitation, left ventricular ejection fraction (LVEF) < 30% (mean 26.4% ± 3.1%), left ventricular end‐diastolic diameter > 7.0 cm (mean 7.3 ± 0.3 cm), and coaptation depth > 1.0 cm. Mean STS‐predicted mortality risk was 22.0% ± 1.5%, and mean EuroSCORE II was 7.0% ± 1.0%. Results: Thirty‐day operative mortality was 2.4% ( n = 1). Significant reverse remodeling occurred: LVEF improved from 26.4% ± 3.1% to 34.6% ± 4.2% ( p < 0.001), and end‐systolic sphericity index decreased from 86.1% to 66.3%. NYHA class improved from 3.5 ± 0.5 to 1.8 ± 0.6 among survivors at 1 year ( p < 0.001). Long‐term survival was 78.5% ± 4.0% at 5 years and 54.8% ± 5.2% at 10 years. Conclusions: In high‐risk end‐stage IsDCM patients, CABG with chordal‐sparing mitral valve replacement and tricuspid annuloplasty facilitates substantial reverse remodeling, durable functional improvement, and excellent long‐term survival. This anatomy‐preserving strategy offers a viable alternative to transplantation or destination therapy for selected patients with advanced heart failure.